Clinical evolution of chronic renal patients with HIV infection in replacement therapy  by Saracho, Ramón et al.
OC
i
R
A
Ó
T
C
J
I
M
E
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
A
R
A
A
c
2
Bn e f r o l o g i a. 2 0 1 5;3 5(5):457–464
Revista de la Sociedad Española de Nefrología
w w w.rev is tanef ro logia .com
riginal article
linical  evolution  of  chronic  renal  patients  with  HIV
nfection in replacement  therapy
amón Sarachoa,∗, Eduardo Martín Escobarb, Jordi Comas Farnésc, Emma Arcosc,
uxiliadora  Mazuecos Blancad, Miguel Ángel Gentil Govantese, Pablo Castro de la Nuezf,
scar  Zurriagag, Manuel Ferrer Alamarg, Encarnación Bouzas Caaman˜oh,
eresa García Falcónh, José Portolés Pérez i, José A. Herrero Calvo i,
arlos Chamorro Jambrina i, Ín˜igo Moina Egurenj, María Teresa Rodrigo de Tomásj,
osé  María Abad Díezk, José I. Sánchez Miretk, Rafael Alvarez Lipek, Rafael Díaz Tejeiro l,
nmaculada Moreno Alía l, Marta Torres Guinea l, Enma Huarte Lozam,
arta  Artamendi Larran˜agam, Carlos Fernández Renedon, Raquel González Fernándezn,
milio  Sánchez Álvarezo, Ramón Alonso de la Torreo
Coordinación de Registros, Sociedad Espan˜ola de Nefrología, Spain
Organización Nacional de Trasplantes (ONT), Spain
Registre de Malalts Renals de Catalunya, Organització Catalana de Trasplantaments, Spain
Servicio de Nefrología, Hospital Universitario Puerta del Mar,  Cádiz, Spain
Servicio de Nefrología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Sistema de Información de la Coordinación Autonómica de Trasplantes de Andalucía (SICATA), Spain
Registre de Malalts Renals de la Comunidad Valenciana (REMRENAL), Spain
Rexistro de Enfermos Renais de Galicia (REXER), Spain
Registro de Enfermos Renales de Madrid-REMER, Spain
Unidad de Información de Pacientes Renales, CA País Vasco (UNIPAR), Spain
Registro de Enfermos Renales de Aragón, Spain
Registro de Enfermos Renales en Tratamiento Sustitutivo de Castilla-La Mancha, Spain
Registro de Enfermos Renales de La Rioja, Spain
Registro de Diálisis y Trasplante de Castilla y León, Spain
Registro de Enfermedades Renales Crónicas de Asturias (RERCA), Spain
a  r  t  i  c  l  e  i  n  f  o
rticle history:
a  b  s  t  r  a  c  t
Patients on renal replacement therapy (RRT) infected with the human immunodeﬁciencyeceived 15 February 2015
ccepted 30 June 2015
vailable online 29 November 2015
virus (HIV) are a special group with growing interest. In order to study the epidemiological
data  of HIV+ patients on RRT in Spain, we collected individual information from 2004 to 2011
(period of use of highly active antiretroviral therapy [HAART]) in the Autonomous Commu-
nities  of Andalusia, Aragon, Asturias, Catalonia, Valencia, Castilla la Mancha, Castilla León,
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Galicia, Madrid, La Rioja and the Basque Country, comprising 85% of the Spanish population.
A  total of 271 incident and 209 prevalent patients were analysed. They were compared
with  the remaining patients on RRT during the same period. The annual incidence was  0.8
patients per one million inhabitants, with a signiﬁcant increase during the follow-up period.
The  proportion of prevalent HIV+ patients was 5.1 per 1000 patients on RRT (95% conﬁdence
interval [CI] 4.4–5.8). Although glomerular diseases constituted the majority of cases (42%),
diabetic nephropathy was the cause in 14% of patients. The nation-wide totals for these
percentages were 13 and 25%, respectively. Compared to the total of patients in treatment,
the risk of death was signiﬁcantly higher in the HIV+ group: hazard ratio (HR) adjusted for
age, sex and diabetes was 2.26 (95%CI 1.74–2.91). Hepatitis C coinfection increased the risk of
death in the HIV+ group (HR 1.77; 95%CI 1.10–2.85). The probability of kidney transplantation
in  HIV+ was only 17% after 7 years, comparing with total RTT patients (HR 0.15; 95%CI:
0.10–0.24).
Despite the use of HAART, the incidence of HIV+ patients on dialysis has increased; their
mortality still exceeds non-HIV patients, and they have a very low rate of transplantation.
It  is necessary to further our knowledge of this disease in order to improve results.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Evolución  clínica  de  los  enfermos  renales  crónicos  en  tratamiento
sustitutivo  con  infección  por  VIH
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r  e  s  u  m  e  n
Los pacientes con infección por el virus de la inmunodeﬁciencia humana (VIH) y enfer-
medad renal que terminan en tratamiento sustitutivo renal constituyen un grupo especial
con  interés creciente para la nefrología. Con el objetivo de conocer datos epidemiológicos de
los  pacientes VHI+ en Espan˜a, recogimos información individualizada durante los an˜os 2004
a  2011 (periodo de uso de tratamiento antiviral de alta eﬁcacia) en las comunidades autóno-
mas  (CCAA) de Andalucía, Aragón, Asturias, Catalun˜a, Comunidad Valenciana, Castilla-La
Mancha, Castilla y León, Galicia, Madrid, La Rioja y País Vasco, que comprendían un 85% de
la  población espan˜ola. Se analizó a un total de 271 pacientes incidentes y 209 prevalentes. Se
compararon con el resto de pacientes en tratamiento sustitutivo durante el mismo periodo
de  tiempo. La incidencia anual fue de 0,8 pacientes por millón de habitantes, con un aumento
signiﬁcativo a lo largo del periodo de seguimiento. La proporción de pacientes prevalentes
VIH+  fue de 5,1/1.000 pacientes en tratamiento sustitutivo, intervalo de conﬁanza (IC) del
95%:  4,4-5,8. Las causas glomerulares constituyeron la mayoría (42%), aunque hubo un 14%
de  nefropatía diabética. En el total de Espan˜a, esos porcentajes son 13 y 25%, respectiva-
mente. Comparando frente al total de pacientes en tratamiento, el riesgo de muerte fue
signiﬁcativamente mayor en el grupo VIH+: hazard ratio (HR) ajustado por edad, sexo y
presencia de diabetes: 2,26 (IC 95%: 1,74-2,91). La coinfección por hepatitis C aumentó el
riesgo de muerte dentro del grupo VIH+: HR 1,77 (IC 95%: 1,10-2,85). La probabilidad de
recibir trasplante renal en los VIH+ solo alcanzó el 17% a los 7 an˜os, comparando con el
total de pacientes en diálisis HR: 0,15 (IC 95%: 0,10-0,24).
A  pesar del uso de las nuevas combinaciones de antivirales, la incidencia de pacientes VIH+
en  diálisis se ha incrementado, su mortalidad supera todavía al resto de pacientes, y tienen
una tasa de trasplante muy baja. Se hace necesario profundizar en el conocimiento de esta
enfermedad para mejorar los resultados.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-NDIntroductionThe proﬁle of patients with human immunodeﬁciency virus
(HIV) infection has changed signiﬁcantly since the mid-1990s,(http://creativecommons.org/licenses/by-nc-nd/4.0/).
following the introduction of highly active anti-retroviral
treatment (HAART). Whilst the majority of patients who
started dialysis in the pre-HAART era did so because of HIV-
associated nephropathy (HIVAN), in recent years the causes
of renal disease in these patients have become more  diverse.
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used were age, as a continuous variable without transforma-n e f r o l o g i a. 2 0 
n addition to HIVAN, the main causes of end stage renal
isease include diabetic nephropathy, nephrosclerosis, and
ephrotoxicity.1 However, the overall incidence of chronic kid-
ey disease requiring renal replacement therapy (CKD-5D) in
hese patients has not decreased.
Patients with HIV infection differ from other renal patient
roups in certain aspects.2 Level of immunocompetence deter-
ines patient selection for the transplant waiting list, and,
o achieve an acceptable survival rate, a special protocol is
eeded for post-transplant management.3 However, despite
he use of speciﬁc protocols, a high rate of delayed graft func-
ion has been observed in patients with HIV.4 In addition, the
o-existence of renal failure and HIV infection increases the
isk of cardiovascular disease.5
In Spain, the incidence and prevalence of HIV infection in
atients with CKD-5D are thought to be low, but there are no
r global studies that quantify these rates.6
There are several publications describing the speciﬁc char-
cteristics of such Spanish patients. This reﬂects an existing
nterest in better understanding this problem.7 Recently, 3
cientiﬁc societies (Sociedad Espan˜ola de Nefrología [Spanish
ociety of Nephrology], Grupo de Estudio del SIDA-SEIMC [AIDS
ask Force and Spanish Society of Infectious Diseases], and
ociedad Espan˜ola de Química Clínica y Enfermedad Molecular
Spanish Society of Clinical Chemistry and Molecular Disease])
roduced an exhaustive consensus document on the assess-
ent and management of renal disease in patients with HIV
nfection. This document contains speciﬁc recommendations
or patients in the various stages of kidney disease, also on
ialysis, and for transplanted patients. It is available on the
ebsites of the 3 participating scientiﬁc societies.8
Currently, almost all the regions in Spain have a registry of
atients with CKD-5D. In addition to basic information, these
egistries contain data on viral infections such as hepatitis B,
epatitis C, and HIV.
In light of the above, we proposed an epidemiological study
n Spain, based on the existing registries. The aim was to
escribe the causes of primary renal disease, the incidence
nd prevalence of HIV infection in dialysis and transplant
atients, survival, and the factors that can inﬂuence survival.
atients  and  methods
e  requested information from the renal patient registries
f the following regions (so called autonomous communities)
n Spain: Andalusia, Aragón, Asturias, Catalonia, Valencian
ommunity, Castile-La Mancha, Castile and León, Galicia,
adrid, La Rioja, and Basque Country. This group of com-
unities encompasses 85% of the total Spanish population.
nformation was collected on patients on renal replacement
herapy with HIV-positive serology. Incident patients were
hose starting renal replacement therapy between 1 January
004 and 31 December 2011, and prevalent patients were those
n renal replacement therapy at 31 December 2011. The fol-
owing variables were collected: date of birth; sex; date and
odality of ﬁrst replacement therapy and subsequent treat-
ents; aetiology of primary kidney disease, coded according
o the European Renal Association-European Dialysis and
ransplantation Association (ERA-EDTA) 1995 coding system;(5):457–464 459
hepatitis B and hepatitis C serological status upon starting
treatment; date of death if applicable; and the autonomous
community where the patient was registered. The data from
the various autonomous communities were grouped together
in one single ﬁle.
For the comparison group, we used a database of all RRT
incident patients between the years 2004 and 2011 from the
same group of autonomous communities (with the excep-
tion of Madrid and La Rioja because their registries did not
include complete information for the same period of time).
This database did not contain information on HIV status. How-
ever, given the low incidence and prevalence of HIV in general,
the risk estimation error in considering the whole group as
unexposed to HIV was negligible. This database comprised
30 693 patients. The results of survival analysis were presented
at the registries meeting of the Sociedad Espan˜ola de Nefrología
(SEN) 2013 conference.9
To calculate incidence, the population of each autonomous
community was taken at the mid-point of the 8-year inter-
val, onJanuary ﬁrst 2008, from the 2001 census estimated
population. To calculate prevalence, the population at 31
December 2011 was used. The data were obtained from the
Instituto Nacional de Estadística (National Institute of Statistics)
(www.ine.es).
Statistical  analysis
Descriptive statistics were used, such as mean, median,
standard deviation, and percentage frequency. For comparison
of frequencies, a standard chi-square test was used; when this
was not appropriate, Fisher’s exact test was used. The com-
parison of means between 2 groups was performed using the
t-test (based on Student’s t-distribution). For adjusted compar-
ison of the proportion of diabetic nephropathy in the group
with HIV vs the whole group, the Mantel–Haenszel method
was used, stratiﬁed by age.
For survival analysis, only the database of RRT incident
patients was used. The Kaplan Meier method was used for
unadjusted analysis and Cox regression was used for adjusted
analysis of survival. The adjustment variables used were age
(as a continuous linear variable), sex, and diabetes as the
cause of primary kidney disease. Diabetes was used because
in different presentations of the Dialysis and Transplant Reg-
istry it was observed that this variable had great prognostic
signiﬁcance.9
In calculating the probability of transplantation over the
study period, the group of incident patients with HIV was com-
pared with the all patients on dialysis. The competing risk
between death and transplantation was taken into account,
because deceased patients would not have the option of trans-
plant, nor could they be considered lost to follow-up. The Fine
and Gray model, as applied by Scrucca,10 was used for the R
project programme. In this model, the adjustment variablestion, and sex. To test what variables were associated with
changes in incidence, Poisson regression was used. The statis-
tical calculations were performed using the software R project
version 2.13, with GNU licence.11
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Fig. 1 – Incidence over the period studied of HIV  infection
in patients on renal replacement therapy, in number of
patients per million population; annual increase in460  n e f r o l o g i a. 2
Results
Incidence,  prevalence,  and  primary  renal  disease
A total of 271 incident patients and 209 prevalent patients were
selected. The demographic data of both groups and the ﬁrst
replacement therapy modality used are shown in Table 1.
The results of annual incidence at the mid-point of the 8-
year period, and the prevalence at 31 December 2011, grouped
by participating community, are presented in Table 2; rates are
expressed as number of patients per million population. The
prevalence of patients with HIV was 5.1 per 1000 patients on
replacement therapy; 95% conﬁdence interval (95%CI), 4.4–5.8
per 1000 patients on replacement therapy.
Using the general data on prevalent and incident patients
from the registries of the participating communities, the pro-
portion of incident patients with HIV over the total incident
patients was calculated at 0.74%. In prevalent patients, this
proportion was 0.51%.
Poisson regression, without adjustment variables, showed
a statistically signiﬁcant increase in the incidence of patients
with on renal replacement therapy from the year 2004 to 2011
(P = .014). With this method, there was an estimated annual
increase of 6.8% (95%CI, 1.3%–12.5%) (Fig. 1).
The frequency of causes of primary renal disease in inci-
dent patients grouped by EDTA registry classiﬁcation, was as
follows: glomerular, 42%; unknown aetiology, 20%; diabetic
nephropathy, 13%; other, 12%; chronic pyelonephritis, 5%;
vascular/hypertensive nephropathy, 5%; polycystic, 2%; and
Table 1 – Demographic data of incident and prevalent patients 
replacement therapy.
HIV+ 
Incident patients 
N 271 209
Mean age (SD) 46.8 (10.8) 45.7
Age (min-max) 15.5–85.9 15.1
Women/men 63/208 48/
1st treatment modality Mo
Haemodialysis 228 147
Peritoneal D. 42 32 
Transplant 1 30 
Table 2 – Number of patients per autonomous community, with
population.
Autonomous community Incident patients Prevalent 
Catalonia 66 44 
Andalusia 58 42 
Madrid 42 41 
Valencian Comm. 41 26 
Basque Country 16 16 
Castile and León 15 9 
Aragón 14 9 
Galicia 11 12 
Castile-La Mancha 4 3 
Asturias 3 6 
La Rioja 1 1 
Total 271 209 incidence, 6.8% (95%CI, 1.3%–12.5%); P = .014.
ischaemic nephropathy, 1%. More detailed causes are shown
in Fig. 2. For the total patients on renal replacement therapy in
the same communities, diabetic nephropathy was the cause
in 22% of incident patients, and glomerular causes affected
12%. In the comparison of the percentage of incident patients
with diabetic nephropathy, between the group with HIV and
those without, adjusting for age category, the rate ratio using
Mantel–Haenszel was 0.50 (95%CI, 0.35–0.71).
There were no signiﬁcant changes in the incidence of each
diagnostic group of primary renal disease in the different years
of follow-up, nor were there differences in aetiology when
with HIV against total control population started on renal
Control
Prevalent patients Incident patients
 30 693
 (10.7) 63.9 (12.5)
–85.9 15.0–96.7
161 11 069/19 624
st recent treatment modality 1st treatment modality
 26 250
3775
668
 calculations of incidence and prevalence per million
patients Annual incidence PMP Prevalence PMP
1.14 6.012
0.901 5.069
0.848 6.418
1.048 5.188
0.935 7.517
0.749 3.630
1.349 6.845
0.503 4.397
0.253 1.463
0.354 5.700
0.401 3.203
0.882 5.349
n e f r o l o g i a. 2 0 1 5;3  5(5):457–464 461
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For survival analysis, we used the cohort of RRT incident
patients with HIV. Of the total 271 patients in this group,
84 patients died. The median survival, estimated using the
Table 3 – Fine and Gray regression model for
proportional risk for time until receiving ﬁrst renal
transplant, grouping together patients with and without
HIV.
HR 95%CI Pig. 2 – Causes of primary renal disease in incident patients 
omparing different periods before and after 2 cut-off points:
anuary ﬁrst 2008 and January ﬁrst 2006.
enal  transplant
uring the period observed, of the 271 incident patients with
IV, 21 patients received at least one renal transplant, one of
hich was for the second time. The cumulative probability of
eceiving a ﬁrst renal transplant during the period observed,
aking into account the competing risks of death and trans-
lantation, was 5%, 10%, and 17%, at 2 years, 5 years, and 7
ears, respectively, vs 19%, 26%, and 32%, for the total patients
n replacement therapy. These are gross comparisons without
djustment for confounding variables.
The risk ratio for receiving a renal transplant for patients
ith HIV compared with patients without HIV was estimated
sing the Fine and Gray competing risks regression model,
djusted for age and sex. This estimation gave a value of
.15 (95%CI, 0.10–0.14). This means that the probability of HIV, according to the EDTA classiﬁcation groups and codes.
receiving a renal transplant during the time studied was
estimated to be 6.6 times lower for patients with HIV than for
patients without HIV, 95%CI, 4.2–10 times (Table 3).
SurvivalSex: female 1.01 0.95–1.06 .85
Age, years 0.94 0.94–0.95 <.001
HIV+ 0.15 0.10–0.24 <.001
462  n e f r o l o g i a. 2 0 1 5;3 5(5):457–464
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Fig. 3 – Overall survival of the patient group with HIV,
according to the Kaplan–Meier estimator, with 95%
conﬁdence intervals as broken lines, and number of
Table 5 – Cox regression model for overall survival in the
cohort of patients with HIV, estimating the effect of
having hepatitis C positive serology, as well as the
effects of age, diabetic nephropathy, and sex.
HR 95%CI P
Sex: female 1.25 0.75–2.10 .390
Age, years 1.03 1.00–1.05 .017
Diabetic nephropathy 1.78 0.97–3.25 .062patients at risk in each year.
Kaplan–Meier method, was 5.75 years (95%CI, 5.13–7.35 years).
The survival graph is shown in Fig. 3.
Using the Cox model, we  investigated variables that could
be associated with survival. The variables investigated were
age, sex, diabetic nephropathy, and period when treatment
was started: either before or after January 2008 (to test if sur-
vival improved over time). None were found to be statistically
signiﬁcant.
Survival was compared between incident patients with
HIV and all incident patients from the same group of com-
munities between the years 2004 and 2011. Cox regression
analysis, adjusted for age, sex, and diabetic nephropathy, esti-
mated a mortality risk for patients with HIV of just over 2
times higher than for patients without HIV; HR, 2.26 (95%CI,
1.74–2.91) (Table 4).
Hepatitis  B  and  hepatitis  C  serology
Of the patients with HIV, 7.8% had co-infection with hepatitis
B (HBsAg+), and 53.1% had anti-hepatitis C antibodies. Given
the low proportion of patients with hepatitis B, no exploratory
analysis was performed for this group. The group that was
seropositive for hepatitis C (HCV) was signiﬁcantly younger,
mean age 45.5 years vs 48.4 years (P = .034). There were no
Table 4 – Cox regression model for overall survival, with
the variables indicated.
HR 95%CI P
Sex: female 0.85 0.81–0.88 <.001
Age, years 1.06 1.57–1.60 <.001
Diabetic nephropathy 1.46 1.39–1.51 <.001
HIV+ 2.26 1.74–2.91 <.001
Estimated effect of having HIV+ serology compared with HIV−  sero-
logy, adjusting for age, sex, and diabetic nephropathy.Hepatitis C+ 1.77 1.10–2.85 .019
signiﬁcant differences for sex, year of starting RRT, or
incidence of diabetic nephropathy.
Using Cox regression, survival in the group of incident
patients with HIV was analysed according to HCV-positive
serology, adjusted for age, sex, and diabetic nephropathy. The
risk of death for patients with HCV coinfection was almost 2
times higher than for patients with HIV monoinfection, HR,
1.77 (95%CI, 1.10–2.85) (Table 5).
Discussion
In Spain, the incidence of HIV infection in patients with CKD-
5D during the period 2004–2011 was almost 1%. This is similar
to that seen in other European series. The prevalence was
lower than this. The prevalence, lower than the incidence,
could be due to a worse survival of this patient group com-
pared to other patients. We  found a progressive increase in
the incidence of HIV, which could not be attributed to an
increase in HIV infection in the general population, as this has
decreased since 1998. It could be related to an older patient
age at time of HIV diagnosis and the increased survival since
the use of HAART. This confers an increased exposure to
risk factors for renal disease, such as toxicity from antivi-
rals, co-infection with HCV, hypertension, dyslipidaemia, and
diabetes.12 There is a great deal of evidence that patients with
HIV infection, independently of sex or age, have a higher risk
of developing atherosclerotic cardiovascular disease.13 HIV is
associated with, and constitutes a risk factor for, chronic kid-
ney disease.
Regarding the proportion of RRT prevalent patients with
HIV in 2011 over patients without HIV on RRT, our results
were very similar to those published by the Spanish group
GESIDA in a survey carried out in 2006,6 and the conﬁdence
intervals overlapped. Five years elapsed between the estima-
tion of these rates, and we  detected an annual increase in the
incidence of HIV. However, it is possible that the progressive
increase in the prevalence of total CKD-5D patients and their
improved survival compensated for the increase in incident
patients with HIV.
If we take the prevalence of HIV infection in the adult pop-
ulation to be 1.5/1000, as was published for the year 2008
in Andalusia,14 then using our data and the data from the
dialysis and transplant registries, we can estimate the preva-
lence ratio of renal replacement therapy in those infected with
HIV in the general population to be 3.5. This ratio, under cer-
15tain conditions, can be interpreted as the relative risk of
developing CKD-5D for those infected with HIV vs the general
population.
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These results also show that infection with HIV in CKD-5D
onfers an increased mortality risk. It is important to put these
ndings into context: the epidemiological data from Catalonia
uring the era of extensive HAART use reported a mortality
or patients with HIV 5 times higher than that of the general
opulation.16 In the last 2 decades, the prognosis of patients
ith HIV has improved substantially. This improvement was
urther reinforced once sufﬁcient experience was acquired for
anagement of the pharmacokinetics of HAART on dialysis.17
t has been reported that this improved survival now equals
hat of patients without HIV: one study conducted in France
oncluded that HIV infection did not increase the risk of death
n patients on dialysis or with a transplant.18 However, the
nalysis of a cohort of patients with HIV that started dialysis
n Spain during the years 1999–2006 observed that their sur-
ival was lower than that of other patients starting dialysis.19
ur results are in line with the second observation, probably
ecause the patients had the same demographic origin and
imilar risk factors.
On top of the already increased risk with HIV, co-infection
ith HCV is associated with yet higher mortality, up to nearly
ouble the risk of death by any cause. It has been reported that
oinfection with HCV is associated with HIV infection through
he intravenous use of illegal drugs, and a longer duration of
IV infection.6 These 2 factors could lead to a worse survival.
The prevalence of HCV in our cohort was double that
eported in Europe2 and was similar to that of other studies
n Spain. This difference could be explained by a higher pro-
ortion of HIV infection via intravenous drug use in Spain. In
ne meta-analysis that included a total of 145 608 patients on
ialysis, HCV-positive serology was associated with a higher
ortality in CKD-5D patients.20 Likewise, in patients with
IV infection without renal disease, HCV coinfection carries a
igher mortality risk.21
The causes of primary renal disease in patients with HIV
iffered from those without HIV when compared with the
ialysis and transplant registry of 2010. There was a notable
redominance of glomerular causes: one third of patients with
IV vs 21% in the general registry. In the group with HIV,
ocal segmental glomerulosclerosis was a predominant cause,
nd probably corresponded to HIV-associated nephropathy
HIVAN), given that a speciﬁc code for HIVAN does not appear
n the EDTA list. Therefore, focal segmental glomeruloscle-
osis likely represents a much lower percentage than that
eported in the American series, as would be expected in a
ountry with a small black population.
Other glomerular causes remained predominant, prob-
bly due to the association between HCV coinfection and
lomerulopathies.22
Although diabetic nephropathy was less common in the
roup with HIV than in the general registry, 13% vs 22%, it
emained a signiﬁcant reason for starting dialysis. A pro-
ressive decrease was demonstrated in the incidence of
IVAN between 1995 and 2004 during the implementation
f HAART.23 Also, in a review of autopsies of patients with
IV on HAART, the diagnosis of nephrosclerosis was one
24f the most common. It appears that in the last 10 years
n Spain, when the use of HAART became widespread, the
pectrum of primary renal disease in patients with HIV has
hanged, with a trend towards diagnoses akin to those of(5):457–464 463
the CKD-5D population without HIV. The lack of changes
in diagnoses over time in our data could be because in the
period studied, HAART was already implemented and there
were no major changes in the treatment of HIV. Therefore,
although HAART has managed to control the course of
HIV infection, the incidence of CKD-5 has not decreased.
Additional strategies are needed for the prevention of other
causes of glomerulonephritis and HIVAN, such as diabetic
nephropathy, vascular causes, and nephrotoxicity.
As anticipated, we observed a low rate of renal transplant
in patients with HIV. Even adjusting for the competing risk
between death and renal transplant, the probability of receiv-
ing a renal transplant was much lower in this group than in the
rest of the patients on dialysis. It was striking that although
HIV infection is not a contra-indication for renal transplant,
patients with HIV are 7 times less likely to receive a renal
transplant than patients without HIV.
Given the low number of transplants performed, just 21,
survival analysis was not performed for this particular group
due to the low statistical power for detecting differences.
In this study, there was a lack of detailed information
including variables such as type and history of antiviral treat-
ment, time with HIV infection, route of transmission, cause
of death, and many  others. Therefore, a more  detailed anal-
ysis was not possible. However, as the study was based on
patient registries, the information obtained was of a high qual-
ity, guaranteed by the established data validation procedures
of the participating registries. Furthermore, we  had access to
all existing cases in the communities studied, which, due to
their demographic characteristics and percentage of the popu-
lation included, can be taken as representative of the Spanish
population as a whole.
We think that this study could serve to increase the under-
standing of the characteristics of patients with HIV and
CKD-5D in Spain and thus continue improving the care for
this serious health problem.
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